L-Deprenyl (Selegeline) introduced for use in parkinson's disease, is implicated to show beneficial effects in epilepsy, alzheimer's disease, cognition, depression and other age related neurological diseases. In this study, we investigated the CNS effects of L-deprenyl with special reference to epilepsy, anxiety and cognition and memory in mice. L-deprenyl (10, 20 and 40 mg/kg) showed a signifi...

This study evaluated whether the caudate-putamen dopamine response that has been observed after deprenyl administration could be attributed exclusively to metabolically generated l-methamphetamine (l-MeAmp). Brain and plasma levels of deprenyl and l-MeAmp were measured after deprenyl (10 mg/kg s.c.) from 10 to 60 min in conscious rats. Peak caudate-putamen levels were observed for deprenyl (15 ...

The role of monoamine oxidase B (MAO-B) in R(-)-deprenyl-mediated rescue of rat facial motoneurons axotomized at postnatal day 14 (P14) was investigated using the (+)- and (-)-enantiomers of deprenyl [S(+)-deprenyl and R(-)-deprenyl]. Previously, doses of R(-)-deprenyl sufficient to inhibit MAO-B were shown to increase the survival of motoneurons following an apparent loss of target-derived tro...

Oxidative stress may play a major role in the aging process and associated cognitive decline. Therefore, antioxidant treatment may alleviate age-related impairment in spatial memory. Cognitive impairment could also involve the age-related morphological alterations of the hippocampal formation. The aim of this study was to examine the relationship between the effects of deprenyl, an irreversible...

During the past decade, much interest has been focused on the potential utility of monoamine oxidase (MAO) type B inhibitors in neurodegenerative diseases, in particular Parkinson’s disease. In this respect, R-deprenyl is the gold standard to which novel therapeutics are compared, providing symptomatic relief when administered either alone or in combination with L-dopa (9,96). While there is li...

The mechanism by which (-) deprenyl enhances cognitive function in Alzheimer's disease (AD) is not yet understood. (-) Deprenyl (0.2 mg/kg/day) was administered intramuscularly to adult male monkeys (n = 6) for 25 days. Control monkeys (n = 6) received physiological saline by the same route. The activity of acetylcholinesterase (AChE) in different brain regions and the dendritic arborization in...

background and objective: deprenyl is a drug for the treatment of parkinson’s disease, where the dopaminergic neurons are the target of this drug. several reports also documented that deprenyl has an effect on the sensory and motor neurons. there are some reports about the mode of action of deprenyl on motoneurons as a neuroprotective agent, while others believe that deprenyl acts as a neurores...

l-Deprenyl [selegiline, (R)-(-)-deprenyl] is a selective inhibitor of monoamine oxidase B (MAO-B) used in the treatment of Parkinson's disease and proposed as an antidepressant and an aid for cigarette-smoking cessation and treatment of psychostimulant abuse. Beneficial therapeutic effects of (R)-(-)-deprenyl may also result from indirect actions. Brain levels of dopamine and beta-phenylethylam...

The symptomatic treatment of moderate or advanced Parkinson's disease with the use of deprenyl as adjunct therapy in combination with levodopa has been clearly established over the past fifteen years. The first report was that of Birkmayer in 1975 followed by Lees and reports from a number of other authors. Clinical observations have concluded that deprenyl combined with levodopa does have a mo...